Chemoprevention of intestinal tumorigenesis in APCmin/+ mice by silibinin

Cancer Research

Volumn 70, Issue 6, 2010, Pages 2368-2378

  Rajamanickam, Subapriya ^a   Velmurugan, Balaiya ^a   Kaur, Manjinder ^a   Singh, Rana P ^a,c   Agarwal, Rajesh ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BETA CATENIN; CARBOXYMETHYLCELLULOSE; CYTOKINE; POLYSORBATE 20; SILIBININ;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER MODEL; CANCER PREVENTION; CARCINOGENESIS; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COLON POLYP; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; GENETIC TRANSCRIPTION; IMMUNOMODULATION; INFLAMMATION; INTESTINAL CARCINOGENESIS; INTESTINE CANCER; INTESTINE POLYP; MALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMALL INTESTINE; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR VOLUME;

ADENOMATOUS POLYPOSIS COLI; ANIMALS; ANTIOXIDANTS; APOPTOSIS; BETA CATENIN; CELL GROWTH PROCESSES; COLORECTAL NEOPLASMS; CYCLIN D1; CYCLOOXYGENASE 2; DINOPROSTONE; DISEASE MODELS, ANIMAL; INTESTINAL POLYPS; INTESTINE, SMALL; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; SILYMARIN; TRANSCRIPTIONAL ACTIVATION;

EID: 77950255061     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3249     Document Type: Article

References (49)

1. Half E, Arber N. Colon cancer: preventive agents and the present status of chemoprevention. Expert Opin Pharmacother 2009;10:211-219
2. Rustgi AK. The genetics of hereditary colon cancer. Genes Dev 2007;21:2525-2538
3. Hegde MR, Roa BB. Detecting mutations in the APC gene in familial adenomatous polyposis (FAP). Curr Protoc Hum Genet 2006;Chapter 10:Unit 10 8.
4. Church JM, McGannon E, Hull-Boiner S, et al. Gastroduodenal polyps in patients with familial adenomatous polyposis. Dis Colon Rectum 1992;35:1170-1173
5. Nugent KP, Spigelman AD, Phillips RK. Life expectancy after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Dis Colon Rectum 1993;36:1059-1062
6. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990;247:322-324
7. Preston SL, Leedham SJ, Oukrif D, et al. The development of duodenal microadenomas in FAP patients: the human correlate of the Min mouse. J Pathol 2008;214:294-301.
8. Corpet DE, Pierre F. Point: from animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 2003;12:391-400.
9. Post-White J, Ladas EJ, Kelly KM. Advances in the use of milk thistle (Silybum marianum). Integr Cancer Ther 2007;6:104-109
10. Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 2001;15:465-489
11. Agarwal C, Singh RP, Dhanalakshmi S, et al. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene 2003;22:8271-8282
12. Kaur M, Agarwal R. Silymarin and epithelial cancer chemoprevention: how close we are to bedside? Toxicol Appl Pharmacol 2007;224:350-359
13. Singh RP, Agarwal R. Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur J Cancer 2005;41:1969-1979
14. Singh RP, Raina K, Sharma G, Agarwal R. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res 2008;14:7773-7780
15. Raina K, Rajamanickam S, Singh RP, Deep G, Chittezhath M, Agarwal R. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2008;68:6822-6830
16. Singh RP, Tyagi A, Sharma G, Mohan S, Agarwal R. Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving downregulation of survivin. Clin Cancer Res 2008;14:300-308
17. Tyagi A, Singh RP, Ramasamy K, et al. Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-κB and signal transducers and activators of transcription 3. Cancer Prev Res (Phila Pa) 2009;2:74-83.
18. Singh RP, Gu M, Agarwal R. Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res 2008;68:2043-2050
19. Velmurugan B, Singh RP, Tyagi A, Agarwal R. Inhibition of azoxymethane-induced colonic aberrant crypt foci formation by silibinin in male Fisher 344 rats. Cancer Prev Res (Phila Pa) 2008;1:376-384
20. Zhao J, Agarwal R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Carcinogenesis 1999;20:2101-2108
21. Giacomelli S, Gallo D, Apollonio P, et al. Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin. Life Sci 2002;70:1447-1459
22. Swamy MV, Patlolla JM, Steele VE, Kopelovich L, Reddy BS, Rao CV. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res 2006;66:7370-7377
23. Shen G, Khor TO, Hu R, et al. Chemoprevention of familial adenomatous polyposis by natural dietary compounds sulforaphane and dibenzoylmethane alone and in combination in ApcMin/+ mouse. Cancer Res 2007;67:9937-9944
24. Maga G, Hubscher U. Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci 2003;116:3051-3060
25. Li J, Yuan J. Caspases in apoptosis and beyond. Oncogene 2008;27:6194-6206
26. Tosetti F, Ferrari N, De Flora S, Albini A. Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 2002;16:2-14.
27. Rasheed S, McDonald PJ, Northover JM, Guenther T. Angiogenesis and hypoxic factors in colorectal cancer. Pathol Res Pract 2008;204:501-510
28. Choi KS, Bae MK, Jeong JW, Moon HE, Kim KW. Hypoxia-induced angiogenesis during carcinogenesis. J Biochem Mol Biol 2003;36:120-127
29. Lin Z, Chen S, Ye C, Zhu S. Nitric oxide synthase expression in human bladder cancer and its relation to angiogenesis. Urol Res 2003;31:232-235
30. Crawford Y, Ferrara N. VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res 2009;335:261-269
31. Marvin MJ, Dahlstrand J, Lendahl U, McKay RD. A rod end deletion in the intermediate filament protein nestin alters its subcellular localization in neuroepithelial cells of transgenic mice. J Cell Sci 1998;111:1951-1961
32. Teranishi N, Naito Z, Ishiwata T, et al. Identification of neovasculature using nestin in colorectal cancer. Int J Oncol 2007;30:593-603.
33. Gavert N, Ben-Ze'ev A. β-Catenin signaling in biological control and cancer. J Cell Biochem 2007;102:820-828
34. Buchanan FG, DuBois RN. Connecting COX-2 and Wnt in cancer. Cancer Cell 2006;9:6-8.
35. 2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009;30:377-386
36. Eisinger AL, Prescott SM, Jones DA, Stafforini DM. The role of cyclooxygenase-2 and prostaglandins in colon cancer. Prostaglandins Other Lipid Mediat 2007;82:147-154
37. Fantini MC, Pallone F. Cytokines: from gut inflammation to colorectal cancer. Curr Drug Targets 2008;9:375-380
38. Seong J, Chung EJ, Kim H, et al. Assessment of biomarkers in paired primary and recurrent colorectal adenocarcinomas. Int J Radiat Oncol Biol Phys 1999;45:1167-1173
39. Milkiewicz M, Ispanovic E, Doyle JL, Haas TL. Regulators of angiogenesis and strategies for their therapeutic manipulation. Int J Biochem Cell Biol 2006;38:333-357
40. Erdamar S, Bagci P, Oz B, Dirican A. Correlation of endothelial nitric oxide synthase and vascular endothelial growth factor expression with malignancy in patients with astrocytic tumors. J BUON 2006;11:213-216
41. Clevers H. Wnt breakers in colon cancer. Cancer Cell 2004;5:5-6.
42. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: cyclin D1: normal and abnormal functions. Endocrinology 2004;145:5439-5447
43. Pishvaian MJ, Byers SW. Biomarkers of WNT signaling. Cancer Biomarkers 2007;3:263-274
44. Giles RH, Lolkema MP, Snijckers CM, et al. Interplay between VHL/HIF1α and Wnt/β-catenin pathways during colorectal tumorigenesis. Oncogene 2006;25:3065-3070
45. Harris RE. Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem 2007;42:93-126.
46. Neufeld G, Kessler O. Pro-angiogenic cytokines and their role in tumor angiogenesis. Cancer Metastasis Rev 2006;25:373-385
47. Bosco MC, Puppo M, Blengio F, et al. Monocytes and dendritic cells in a hypoxic environment: spotlights on chemotaxis and migration. Immunobiology 2008;213:733-749
48. Cruz-Munoz W, Khokha R. The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit Rev Clin Lab Sci 2008;45:291-338.
49. Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest 2000;117:1162-1172